Voyager Therapeutics, Inc. Common Stock (VYGR) is a publicly traded Healthcare sector company. As of May 21, 2026, VYGR trades at $3.52 with a market cap of $213.29M and a P/E ratio of -1.78. VYGR moved +0.86% today. Year to date, VYGR is -14.22%; over the trailing twelve months it is +2.94%. Its 52-week range spans $2.65 to $8.28. Analyst consensus is strong buy with an average price target of $15.14. Rallies surfaces VYGR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Voyager Therapeutics Q1 Cash $171.7M Runway into 2028, $27.9M Loss: Voyager Therapeutics ended Q1 2026 with $171.7 million in cash and marketable securities, providing runway into 2028, and reported a net loss of $27.9 million. Collaboration revenue declined to $2.6 million while R&D expenses decreased to $24.6 million on cost-efficiency measures.
| Metric | Value |
|---|---|
| Price | $3.52 |
| Market Cap | $213.29M |
| P/E Ratio | -1.78 |
| EPS | $-1.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.28 |
| 52-Week Low | $2.65 |
| Volume | 535 |
| Avg Volume | 0 |
| Revenue (TTM) | $36.49M |
| Net Income | $-116.64M |
| Gross Margin | 0.00% |
9 analysts cover VYGR: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.14.